Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

35.22 -1.81 (-4.89%)
Streaming Delayed Price Updated: 12:00 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Market Mixes It Up With A Broad Rally ↗
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Here's Why This Little-Known Growth Stock Is a Buy ↗
Analysts think this genomic test maker could have major upside in the next year. 
Via The Motley Fool
News headline image
Looking Into Veracyte's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Recap: Veracyte Q1 Earnings ↗
 
Via Benzinga
News headline image
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Time To Play Small Cap Life Science Stocks ↗
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
News headline image
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
News headline image
Something Happened In Biotech Last Week ↗
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
News headline image
Veracyte Announces First Quarter 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
From Veracyte, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 4, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million. 
Via Benzinga
News headline image
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
From Veracyte, Inc.
Via Business Wire
News headline image
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
News headline image
Veracyte Announces Release of Inaugural ESG Report
From Veracyte, Inc.
Via Business Wire
News headline image
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
News headline image
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
News headline image
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
From Veracyte, Inc.
Via Business Wire
News headline image
7 Biotech Stocks That Could Be the Next Big Thing ↗
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
News headline image
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
From Veracyte, Inc.
Via Business Wire
News headline image
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors? ↗
This diagnostics test maker has held up well over the last year. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.